Pharma-Sana SRL
Pharma-Sana reported total assets of 487,904 € at the end of the 2025 financial year (annual accounts filed with the NBB on 25 Sep 2026).
The score of Pharma-Sana shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +146 % Total assets -3 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Pharma-Sana's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 135,482 € | ||||
| Equity | 306,818 € | ||||
| Cash | 169,888 € | ||||
| EBITDA | 230,418 € | ||||
| Total assets | 487,904 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 25 Sep 2026
- Year ended 31 Dec 2024filed on 18 Jul 2025
- Year ended 31 Dec 2023filed on 22 Aug 2024
- Year ended 31 Dec 2022filed on 27 Aug 2023
- Year ended 31 Dec 2021filed on 31 Jul 2022
Pharma-Sana's financial analysis
- Solvency62.9%sector median: 37.8%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Pharma-Sana
Pharma-Sana's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0883.740.769
- VAT number
- BE0883740769
- Peppol
- Registered · 0208:0883740769 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 26 Sep 2006
- Registered office
- 1030 Schaerbeek
- Latest accounts
- 2025 · filed on 25 Sep 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Pharma-Sana (SRL) has been based in Schaerbeek since 2006, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 135,482 € and equity of 306,818 €; its revenue is not published. Its solvency stands at 62.9%, above the median of its sector (37.8%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Pharma-Sana
Companies in the same business, of comparable size and area, outside its group.
- Apotheek Vandewalle Retail sale of pharmaceutical products Ghent · balance sheet 488,284 €
- Arendsapotheek Retail sale of pharmaceutical products Harelbeke · balance sheet 488,654 €
- Pharmacie Oreins Delivyne Retail sale of pharmaceutical products Tournai · balance sheet 486,536 €
- Medifar Retail sale of pharmaceutical products Izegem · balance sheet 490,803 €
- Walemapotheek Retail sale of pharmaceutical products Mechelen · balance sheet 491,415 €
- Audopharma Retail sale of pharmaceutical products De Panne · balance sheet 483,083 €
- Internationale Apotheek Retail sale of pharmaceutical products Antwerp · balance sheet 483,003 €
- Pharmaro Retail sale of pharmaceutical products Charleroi · balance sheet 493,235 €
Frequently asked questions about Pharma-Sana
What is the revenue of Pharma-Sana?
Pharma-Sana files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Pharma-Sana?
In Belgium, the VAT number is the company number prefixed with BE: BE0883740769 for Pharma-Sana, if the company is VAT-registered. Its company number (CBE) is 0883.740.769.
Where is the registered office of Pharma-Sana?
According to the CBE register, the registered office of Pharma-Sana is in 1030 Schaerbeek.
What is the equity of Pharma-Sana?
At the close of the 2025 financial year, the equity of Pharma-Sana amounts to 306,818 €, a solvency of 62.9% of total assets.
Who manages Pharma-Sana?
The register lists 1 active mandates at Pharma-Sana. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Pharma-Sana
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →